Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance from its cardiovascular and immunology products.
The Swiss pharma giant said net sales rose 16% in the fourth quarter to $13.2 billion, contributing to full-year revenue of $50.3 billion. Core operating income increased 29% to $4.9 billion, while net income climbed 6% to $2.8 billion, and core earnings per share (EPS) grew 33% to $1.98.
Entresto (sacubitril/valsartan) saw 34% growth in the quarter, supported by higher adoption in heart failure treatment, while immunology drugs Cosentyx (secukinumab) and Kesimpta (ofatumumab) grew 24% and 49% respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze